Change in Ownership Ratio in Regenerative Medicine カジノ シークレット 登録 Cell Therapy CDMO

Sep. 30, 2024

カジノ シークレット 登録 Chemical Co., Ltd.
カジノ シークレット 登録 Pharma Co., Ltd.

Sumitomo Chemical Company Limited (Head Office: Chuo-ku, Tokyo, Japan; "Sumitomo Chemical") カジノ シークレット 登録 Sumitomo Pharma Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; "Sumitomo Pharma") announced today that they have agreed to change their respective ownership ratios in their joint venture Contract Development カジノ シークレット 登録 Manufacturing Organization (CDMO), S-RACMO Co., Ltd. (“S-RACMO”), a company that develops manufacturing methods カジノ シークレット 登録 manufactures products for the regenerative medicine カジノ シークレット 登録 cell therapy field. On October 1, 2024, Sumitomo Chemical’s ownership ratio will increase to 66.6% from 49%, カジノ シークレット 登録 it will lead the CDMO’s business operations.

The field of cell therapy had a market size of approximately billion in 2022, カジノ シークレット 登録 it is expected to grow rapidly at an annual rate of 10-15% going forward. S-RACMO was established カジノ シークレット 登録 began business operations in 2020. It has been leveraging Sumitomo Chemical’s platform technology in iPS/ES cells, along with its know-how as a contract manufacturer of pharmaceuticals, while also taking advantage of Sumitomo Pharma’s expertise gained by developing sophisticated manufacturing methods カジノ シークレット 登録 pharmaceutical development through its many years of research カジノ シークレット 登録 multiple projects in the regenerative medicine カジノ シークレット 登録 cell therapy business. Combining these strengths, S-RACMO has been working to deepen カジノ シークレット 登録 further enhance its capabilities as a CDMO in the regenerative medicine カジノ シークレット 登録 cell therapy field. In addition to a manufacturing facility whose establishment was completed in 2021, it is in the midst of constructing a new manufacturing facility that is scheduled to be completed in 2025. In terms of its financial performance, as well, it has recorded profits in three consecutive years since fiscal 2021, while also achieving increasing profits.

As announced at its Investors' Meeting for the Current Priority Management Issues カジノ シークレット 登録 Business Strategy held on April 30, 2024, Sumitomo Chemical has positioned the advanced medical solutions business as a new core area for growth, starting with its CDMO business in active ingredients カジノ シークレット 登録 intermediates for small molecule drugs as well as in regenerative medicine カジノ シークレット 登録 cell therapies. It is moving ahead in developing this business as a next-generation growth driver. The increase its ownership ratio announced today is an expression of Sumitomo Chemical’s commitment to further developing the regenerative medicine カジノ シークレット 登録 cell therapy CDMO business. Under Sumitomo Chemical’s leadership, S-RACMO will accelerate its business, using the new manufacturing facility currently under construction in Osaka カジノ シークレット 登録 entering the US market.

Sumitomo Pharma, meanwhile, is positioning itself as a frontrunner in developing cell therapy products using iPS cells in the regenerative medicine カジノ シークレット 登録 cell therapy business. It is aiming to bring to market the world’s first cell therapy product derived from iPS cells. To maximize group synergies in the research カジノ シークレット 登録 development of regenerative medicine カジノ シークレット 登録 cell therapies as well as their manufacturing カジノ シークレット 登録 sales organization, Sumitomo Chemical カジノ シークレット 登録 Sumitomo Pharma plan to establish a new joint company within fiscal 2024. They plan to publicly announce further details at an appropriate time once further details are determined.

Outline of the CDMO in the Regenerative Medicine カジノ シークレット 登録 Cell Therapy Field

Company name	S-RACMO Co., Ltd. S-RACMO is an acronym of Sumitomo カジノ シークレット 登録 Regenerative カジノ シークレット 登録 Cellular Medicine Organization.
Address	33-94 Enoki-cho, Suita, Osaka, Japan (on the premises of カジノ シークレット 登録 Pharma's Central Research Laboratories)
Representative Director カジノ シークレット 登録 President	Atsushi Tsuchida
Lカジノ シークレット 登録es of busカジノ シークレット 登録ess	CDMO of development of manufacturing methods カジノ シークレット 登録 manufacturing for regenerative medicine カジノ シークレット 登録 cell therapy products.
Capital	￥50 million
Established on	September 1, 2020
Ownership ratios	カジノ シークレット 登録 Chemical 66.6%, カジノ シークレット 登録 Pharma 33.4% (starting October 1, 2024)

Outline of the New Regenerative Medicine カジノ シークレット 登録 Cell Therapy Manufacturing Facility Being Built

Address	33-94 Enoki-cho, Suita, Osaka, Japan (on the premises of カジノ シークレット 登録 Pharma's Central Research Laboratories)
Buildカジノ シークレット 登録g size	2 stories
Buildカジノ シークレット 登録g area	Approx. 1,800m2
Start of construction	January 2021(plan)
Construction start	July 2024
Completion	July 2025 (plan)

Contact